Volasertib, a small molecule inhibitor of the polo-like kinase 1 (PLK1) protein, was combined with low-dose cytarabine and compared to low-dose cytarabine alone in a randomized, phase II trial for unfit patients with AML. The gene discussed is PLK1; the disease is acute myeloid leukemia.